What can sponsors and CROs do to reduce avoidable delays and make recruitment more predictable?
As oncology trials become more biomarker-driven and patient populations harder to identify, effective pre-screening and patient identification are becoming increasingly important. In this webinar, experts from Pratia, P1 Pratia Oncology, Pratia Sirius and a guest speaker from Society for Clinical Research Sites (SCRS) examine how patient identification, referral pathways and site capabilities can vary between Phase I and later-phase studies, helping sponsors and CROs consider these differences when planning recruitment strategies. The discussion also compares the practical realities of running oncology trials across the US and Europe.
:quality(70))